What factors of GLP-1 coverage drive up premiums Using data from MarketScan and research by Blue Health Intelligence (BHI), the EBRI report models how GLP-1 coverage could affect employer-sponsored insurance premiums, exploring several scenarios based on: Drug pricing Net costs range from $617 to $766 per 30-day supply Patient adherence Perfect adherence leads to higher premiums due to sustained drug use Eligibility criteria Including overweight individuals with at least one weight-related condition significantly increases cost burden Cost-sharing Cost-sharing structures such as $90 copays help but dont eliminate increases Usage is growing More than 57 million privately insured adults qualify for GLP-1 drugs, like Ozempic and Wegovy
As awareness grows among both patients and healthcare providers, companion nutrition is increasingly becoming an essential part of the overall treatment journey rather than an optional add-on
Product Attributes CAS # : 1034043-18-3 Molecular Formula : C10H11N2+ (free base), C10H11IN2 (iodide salt), C10H11ClN2 (chloride salt) Sequence (AA) : N/A (small molecule) Molecular Weight : 215.26 g/mol PubChem CID : 950107 (free base), 66522933 (iodide salt) Half-Life : 3.8-6.9 hours Synonyms : 5-Amino-1-methylquinolinium-1-ium, NNMT Inhibitor 5A1MQ, NNMTi, Amino-1MQ, 1-MQ, Type : Synthetic small molecule analog Research Focus : Weight Loss, Mitochondrial Function, Longevity, Metabolic Health Scientific References Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Animal Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes mellitus Review What is 5-Amino-1MQ
FDA warnings about semaglutide dosing errors This is not theoretical